Market Intel: Bioelectronics, Imaging Fortify Medtech's Defense Against Rheumatoid Arthritis
Executive Summary
As rheumatoid arthritis treatment improves in the biologics era, patients need fewer joint replacements. Instead, they now require more closely monitored, agile care, in the face of a growing shortage of qualified rheumatologists. These demands help propel digital health applications, bioelectronic devices and novel imaging modalities into the medtech spotlight.
You may also be interested in...
SetPoint Medical Starts Testing Unique Neuromodulation Device In Rheumatoid Arthritis Patients
SetPoint Medical announced the launch of a multicenter clinical trial to test its vagus nerve stimulation system in rheumatoid arthritis patients who did not adequately respond to multiple biologic agents. Among the company's backers are Medtronic, Boston Scientific and GSK.
M&A Analysis: M&A Rises In 2017 As Market Set To Bounce Back In 2018
2017 proved to be a busy year for medtech M&A activity, with the number of deals rising from 174 in 2016, to 206 in 2017. The year also brought a number of notable acquisitions, including Becton Dickinson's blockbuster $24bn purchase of CR Bard and Dutch health-care giant Philips undertaking an ambitious acquisition spree. Medtech Insight takes a look at the highlights of 2017 and what's in store for 2018.
SetPoint Turns Up The Heat On Rheumatoid Arthritis Program
Having raised $30m in its latest financing round, SetPoint Medical is now focusing squarely on its rheumatoid arthritis program. The neuromodulation company, which counts Medtronic, Boston Scientific and GSK among its investors, is aiming to kick off Phase II trials before the end of the year, using a commercial-ready version of its implantable vagal nerve stimulation technology.